Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81.

2.

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.

3.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60.

4.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

5.

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG.

Blood. 2010 Apr 29;115(17):3589-97. doi: 10.1182/blood-2009-04-215848.

6.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Review.

PMID:
16919893
7.

Characterization of murine JAK2V617F-positive myeloproliferative disease.

Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW.

Cancer Res. 2006 Dec 1;66(23):11156-65.

8.

Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.

Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL.

Blood. 2012 Jul 5;120(1):166-72. doi: 10.1182/blood-2012-01-402396.

10.

Critical requirement for Stat5 in a mouse model of polycythemia vera.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Apr 12;119(15):3539-49. doi: 10.1182/blood-2011-03-345215.

11.

Polycythemia vera: scientific advances and current practice.

Tefferi A, Spivak JL.

Semin Hematol. 2005 Oct;42(4):206-20. Review.

PMID:
16210034
12.

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.

Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K.

Leukemia. 2008 Jan;22(1):87-95.

PMID:
18033315
13.

Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.

Ann Hematol. 2007 Apr;86(4):245-53.

PMID:
17262192
14.

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7.

15.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
16.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
17.

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, Vainchenker W, Villeval JL.

Blood. 2010 Aug 5;116(5):783-7. doi: 10.1182/blood-2009-12-257063.

18.

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR.

N Engl J Med. 2007 Feb 1;356(5):459-68.

19.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.

Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.

Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

PMID:
25171702
20.

The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.

Kirabo A, Park SO, Wamsley HL, Gali M, Baskin R, Reinhard MK, Zhao ZJ, Bisht KS, Keserű GM, Cogle CR, Sayeski PP.

Am J Pathol. 2012 Sep;181(3):858-65. doi: 10.1016/j.ajpath.2012.05.033.

Items per page

Supplemental Content

Support Center